Why did Corcept, Johnson & Johnson, and Southwest Airlines fall on April 1, 2025?
Corcept, Johnson & Johnson, and Southwest Airlines lead US stock losses as biotech and airline sectors react to trade policy jitters on April 1, 2025. Read More
Johnson & Johnson’s $55bn bet: What it means for healthcare and investors
Johnson & Johnson is investing $55 billion in U.S. manufacturing, R&D, and technology, reinforcing its leadership in pharmaceuticals. Find out more. Read More
Johnson & Johnson’s icotrokinra demonstrates superiority in plaque psoriasis trials, setting stage for market disruption
New clinical trial data from Johnson & Johnson suggests that icotrokinra results could mark a major shift in plaque psoriasis treatment, demonstrating strong efficacy and ... Read More
Janssen’s subcutaneous amivantamab gains CHMP backing for EGFR-mutated lung cancer
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the extension of marketing ... Read More
Johnson & Johnson to acquire Intra-Cellular Therapies in $14.6bn deal
Johnson & Johnson has announced its largest biotech acquisition in over a year, agreeing to purchase Intra-Cellular Therapies for $14.6 billion. The deal highlights the ... Read More
Johnson & Johnson’s RYBREVANT and LAZCLUZE show unprecedented survival advantage in lung cancer trial
Johnson & Johnson has revealed transformative results from the Phase 3 MARIPOSA clinical trial, positioning the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) as a ... Read More
Biotech breakthrough: Mersana Therapeutics stock soars 23% after blowing past Q3 expectations
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment, saw its shares leap by 23% following a robust ... Read More
FDA greenlights Medtronic’s dual-energy ablation—could this be the future of AFib treatment?
Medtronic has achieved a major milestone with the U.S. Food and Drug Administration (FDA) granting approval for its Affera Mapping and Ablation System, including the ... Read More
Indoco Remedies secures final USFDA approval for generic Cetirizine Hydrochloride tablets
Indoco Remedies Limited has secured a significant regulatory win by receiving final approval from the United States Food and Drug Administration (USFDA) for its generic ... Read More
Johnson & Johnson’s RYBREVANT approved by FDA as second-line option for EGFR-mutated NSCL
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's RYBREVANT (amivantamab-vmjw) in combination with chemotherapy for the treatment of adult patients with ... Read More